Benchling is a private company building in biotech/research software, founded in 2013. Investors last valued the company at $6.1B. No public ticker exists for the company.
One company valuation: $6.1B, dated Nov 2021.
Altimeter CapitalLEADSSequoia Capital Global EquitiesLEAD
Menlo VenturesLEAD
Thrive CapitalLEAD
Tiger GlobalSSequoia CapitalAltimeter CapitalSequoia Capital Global EquitiesMenlo VenturesBenchling is a cloud-based platform for biotechnology research and development, positioned as the only biology-first platform for scientific data, collaboration and analysis. Founded in 2012 by Sajith Wickramasekara, Benchling has 750 employees, and innovative academics, startups, and more than half of the world's top 50 biopharma companies rely on Benchling as customers.
Benchling's mission is to accelerate CRISPR gene engineering, cell therapies, lab-grown meat, synthetic biology, biofuels, and biomaterials, and the company says it is loved by 200,000 scientists and counting.
Listed funds carry late-stage private names. A fund's latest schedule of investments shows whether it holds Benchling.
Often trade at a premium or discount to NAV.
Platforms match existing holders with buyers. Benchling availability at any moment is set by the holders.
High minimums, transfer approval, company right-of-first-refusal.
Valuations, rounds and IPO status for every company in the directory — Benchling included.
The last valuation is $6.1B.
Lead investors for each round are in the funding timeline.
The closest biotech/research software peers are on the competitors page.
The routes section explains what is realistically available for a company at this stage.
No. Benchling is a private company; its shares do not trade on a public exchange.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
